LYTIR

Insider · SEC Form 4 · Chief Business Officer

Jeffrey Arcara

Filed with the SEC as Arcara Jeffrey; the order above is the one the filer's own signature uses.

In the 12 months to Nov 19, 2026, on the open market: bought $50K of CRVS. Filed a median of 1 business day after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

  1. CRVSBought: Corvus Pharmaceuticals, Inc. Nov 13, 2026 1,003 shares filed Nov 13, 2026 2 transactions filing $11K
  2. CRVSBought: Corvus Pharmaceuticals, Inc. Nov 12, 2026 497 shares filed Nov 13, 2026 3,497 shares held directly after, as filed filing $6K
  3. CRVSBought: Corvus Pharmaceuticals, Inc. Nov 11, 2026 3,000 shares filed Nov 13, 2026 3,000 shares held directly after, as filed filing $34K

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.